排名前五的靶点	数量

DYRK1A(双特异性酪氨酸-磷酸化调控激酶-1A)	3
EZH2(组蛋白赖氨酸甲基化酶EZH2)	2
HDACs(组蛋白去乙酰化酶家族)	2
DNA	2
EphA2(A型肝配蛋白受体-2)	1

关联

项与台北医学大学相关的药物

Artenimol

双氢青蒿素

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1997-01-01

Fucoidan

褐藻多糖硫酸酯

靶点

CLEC-2 x CTNNB

作用机制

CLEC-2 agonists [+1]

在研机构

台北医学大学 [+2]

原研机构

南京医科大学第一附属医院

在研适应症

幽门螺杆菌感染 [+3]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期-

Imofinostat

靶点

HDAC1 x HDAC2 x HDAC3

作用机制

HDAC1抑制剂 [+2]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床1期

首次获批国家/地区-

首次获批日期-

367

项与台北医学大学相关的临床试验

NCT06930313

/ Not yet recruitingN/AIIT

Development and Evaluation of a Brief Compassion-Based Intervention for Managing Depression and Anxiety in Family Caregivers of Lung Cancer Patients: A Mixed Methods Randomized Controlled Trial

Objectives: This 3-year study aims to develop, refine, and evaluate a brief compassion-based intervention specifically designed for family caregivers of lung cancer patients. In the first year, the primary focus will be on developing the intervention content and assessing its feasibility and acceptability. In the second and third years, the goal will be to assess the intervention's effects on depression and anxiety.
Method: In the first year, the intervention will be developed in three stages. Initially, the intervention will be created based on compassion-focused theory and evidence-based exercises, incorporating feedback from family caregivers in previous studies and insights from professionals to ensure its relevance to lung cancer caregivers. Next, a pilot study will test the intervention's feasibility and acceptability with 30 family caregivers, using mixed methods to gather session-by-session feedback and assess recruitment, retention, and adherence. Following the pilot, the intervention will be revised based on participant and researcher feedback, preparing it for further study. In the second and third years, a randomized controlled trial (RCT) will be conducted with 84 participants randomly assigned to either the 4-session Brief Compassion-Based Intervention (BCI) or a single-session Telephone-Based Support and Education (TSE) control group. Outcomes, including depression, anxiety, caregiver stress, mindfulness, self-compassion, and self-efficacy, will be measured at baseline, immediately post-intervention, and at 3- and 6-month follow-ups. For data analysis, long-term follow-up quantitative data will be analyzed using the Generalized Estimating Equation (GEE) to examine group differences. Moderation and mediation analyses will be conducted to explore potential moderators and mechanisms of the intervention. Qualitative data from interviews will be analyzed using content analysis.
Expected Results: This study is expected to provide a comprehensive understanding of the feasibility, acceptability, and effectiveness of compassion-based interventions for lung cancer caregivers, contributing to their application in clinical care practice.

开始日期2026-03-01

申办/合作机构

台北医学大学

[+1]

NCT06487650

/ Not yet recruitingN/AIIT

The Development and Evaluation of Sleep Intervention for Perinatal Family

Background: Sleep disruptions and disturbances are highly prevalent among new mothers and fathers and negatively affect their mental health and infant development outcomes. Effective sleep interventions are vital for family health.
Objectives: To develop a sleep intervention for mother-father-infant triads, and to evaluate the effects on sleep improvement, emotional distress, and infant health outcomes.
Methods: In this proposal, we plan to conduct a parallel-group two-arm randomized controlled trial on pregnant women and their partners. Mother-father-infant triads will be recruited and randomly allocated to the intervention group (receiving a sleep intervention) or the control group. Data will be collected with repeated measures, and the relationship between studied variables will be analyzed with descriptive and inferential statistics.
Anticipatory results: The development and evaluation of an evidence-based sleep intervention will provide a scientific insight into sleep care for pregnant women and their families.

开始日期2025-12-01

申办/合作机构

台北医学大学

NCT07044492

/ Not yet recruitingN/AIIT

The Effectiveness of Empathy-Based Program on Empathy Level Among Nursing Assistants in Long-term Care Facility

This randomized controlled trial aims to explore the impact of an Empathy-Based Program on the level of empathy among nursing assistants in a long-term care facility. A total of 100 participants will be divided into two groups: a virtual reality (VR) with debriefing group, and a control group (C) receiving routine care. The intervention involves a weekly 5-minute VR session featuring immersive experiences of residents' lives within the facility, followed by a 25-minute debriefing discussion in small groups of 5
6 participants. This will continue for three weeks. The study will evaluate the effectiveness of the empathy program in enhancing nursing assistants' empathy levels, with data collection occurring at three time points: baseline, post-intervention, and one-month follow-up.

开始日期2025-09-01

申办/合作机构

台北医学大学

100 项与台北医学大学相关的临床结果

登录后查看更多信息

0 项与台北医学大学相关的专利（医药）

登录后查看更多信息

22,721

项与台北医学大学相关的文献（医药）

2026-02-01·BIOMATERIALS

Targeted immunomodulation with H2-generating nanostructures to mitigate obesity-induced inflammation and metabolic dysfunctions

Article

作者: Pham, Uyen Nu Thu ; Ngo, Thi-Lan-Huong ; Pan, Wen-Yu ; Chou, Kun-Chi ; Ruan, Ting ; Lin, Yu-Jung

Obesity-induced inflammation in visceral adipose tissue (VAT) is a major driver of metabolic dysfunctions, contributing to severe health conditions such as insulin resistance, diabetes, and fatty liver disease. Current anti-inflammatory therapies lack specificity, often leading to systemic immune suppression. To address this challenge, this study develops a nanosilicon-based hydrogen (H₂)-generating nanostructure coated with a positively charged copolymer layer, specifically designed for targeted immunomodulation within VAT. Following intraperitoneal administration in high-fat diet-fed obese mice, the positively charged H₂-generating nanostructure selectively accumulates in the expanded extracellular matrix of obese VAT through electrostatic attraction to its negatively charged components. Once accumulation, it reacts with body fluids to sustainably generates H₂. This continuous H₂ release reprograms the local immune microenvironment by balancing pro-inflammatory M1 and anti-inflammatory M2 adipose tissue macrophages, effectively mitigating VAT inflammation and restoring adipocyte function. In addition to its localized effects, this intervention improves systemic lipid and glucose metabolism, highlighting its potential to address obesity-associated metabolic dysfunctions. By targeting VAT inflammation with high specificity and minimal side effects, this H₂-based nanotechnology offers a promising therapeutic strategy for obesity and its related metabolic disorders.

2026-02-01·BIOMATERIALS

Endogenous macrophages as "Trojan horses" for targeted oral delivery of mRNA-encoded cytokines in tumor microenvironment immunotherapy

Article

作者: Peng, Sheng-Yao ; Chang, Wan-An ; Guo, Jhih-Syuan ; Chen, Yin-Hsu ; Luo, Po-Kai ; Chang, Hsiao-Huang ; Wei, Hao-Chi ; Chuang, Ya-Han ; Lai, Po-Liang ; Nguyen, Lam-Duc-Huy ; Chu, Li-An ; Sung, Hsing-Wen ; Wang, Kuan-Lin

Macrophages (MΦ) in the tumor microenvironment (TME) are often skewed toward the M2 phenotype, which suppresses immune responses and supports tumor progression. Interferon-γ (IFN-γ) plays a pivotal role in reprogramming MΦ toward a pro-inflammatory M1-like phenotype, thereby enhancing anti-tumor immunity. This study introduces a targeted oral immunotherapy strategy using IFN-γ mRNA-loaded lipid nanoparticles conjugated with β-glucans (IFN-γ mRNA@βGlus-LNPs), evaluated in a mouse model of triple-negative breast cancer. Following oral administration, the nanoparticles target transcytotic M cells in Peyer's patches, are taken up by endogenous MΦ in intestinal lymphoid tissues, and transported via lymphatic and systemic circulation to the tumor site. In the TME, the nanoparticles induce transient, localized IFN-γ expression, reprogramming both infiltrating and resident MΦ toward an M1-like phenotype and activating cytotoxic T cell responses. By harnessing the natural tumor-homing ability and biocompatibility of MΦ, this "Trojan horse" approach offers a promising platform for effective, safe mRNA-based cancer immunotherapy.

2026-02-01·COMPUTATIONAL BIOLOGY AND CHEMISTRY

A unified graph-based approach for protein function prediction using AlphaFold structures and sequence features

Article

作者: Nguyen, Thi-Tuyen ; Nguyen, Van-Nui ; Zheng, Wenqing ; Chua, Matthew Chin Heng ; Le, Nguyen Quoc Khanh

Predicting protein function is a key challenge in computational biology with broad implications for understanding biological systems and disease mechanisms. Traditional deep learning approaches rely heavily on protein sequence data and protein-protein interaction (PPI) networks, often neglecting structural information due to limited availability of experimentally resolved protein structures. The advent of AlphaFold, which predicts protein structures with near-atomic accuracy, provides an opportunity to integrate structural context into function prediction. In this study, we propose StructSeq2GO, a novel hybrid model that combines structural and sequence information. StructSeq2GO employs graph representation learning to extract structural features from AlphaFold-predicted protein structures and integrates them with sequence embeddings derived from the ProteinBERT language model to predict Gene Ontology (GO) labels. Experimental evaluations demonstrate that StructSeq2GO achieves state-of-the-art performance across three GO domains, with F_max scores of 0.485, 0.681, and 0.663, AUC scores of 0.764, 0.939, and 0.891, and AUPR scores of 0.688, 0.763, and 0.702 for the Biological Process (BPO), Cellular Component (CCO), and Molecular Function (MFO) ontologies, respectively. These results highlight the critical importance of structural information and the efficacy of ProteinBERT in enhancing protein function prediction, as structure provides spatial and biochemical context not captured by sequence alone. The model's performance is influenced by the quality of AlphaFold structural predictions and may benefit from future improvements in structure confidence modeling. Additionally, extending StructSeq2GO to predict pathway-level or disease-related annotations could broaden its biological utility.

项与台北医学大学相关的新闻（医药）

2025-07-21

·赛柏蓝

二甲双胍，又发现新作用

作者 | 晓琳编辑 | 郑瑶首次发现，二甲双胍可降低这类患癌风险。01 服用二甲双胍与肠癌风险降低有关近日，我国台北医学大学、中山医学大学和辅仁大学组成的研究团队在期刊《Journal of the National Cancer Institute》发布一项与二甲双胍有关的重要研究成果，即二甲双胍的使用与结直肠癌风险降低56％相关，与全因死亡率降低32％相关。这也是科学家首次在炎症性肠病患者群体中发现，服用二甲双胍与肠癌风险降低有关。无独有偶，最近，来自美国加州大学圣地亚哥分校的一项研究发现，与使用磺酰脲类药物的患者相比，服用二甲双胍的2型糖尿病女性活到90岁及以上的几率提升了整整30％；来自图宾根大学和德国图宾根神经退行性疾病中心的研究人员发现，在帕金森病中，大脑区域负责运动控制的大量神经细胞会死亡，而二甲双胍可以起到保护细胞的作用。截止到目前，据赛柏蓝不完全梳理，二甲双胍在抗衰老、防癌、减肥、降血压、调血脂、预防血栓、修护心脏、预防老年痴呆、改善脂肪肝、调节激素、抗炎、改善肠道菌群等40余项作用。02复方降糖药市场快速增长“二甲双胍+”成焦点当然，二甲双胍的这些新作用仍需进一步研究，对于非糖尿病患者来说，自行服用二甲双胍存在一定风险。二甲双胍从1957年进入临床应用已有近70年的历史，作为治疗2型糖尿病的一线药物，进入集采后，销量快速增加。国家医保局曾表示，集采后2023年全国医疗机构使用二甲双胍集采中选药品114亿片，其中0.25g规格的用量为46亿片，0.5g规格的用量为68亿片，中选二甲双胍用量占该药品总用量的84%。今年6月，中国疾病预防控制中心慢病中心发布一组数据，2023年我国糖尿病患者数量已达2.33亿，占全球糖尿病人口的四分之一，这为二甲双胍市场提供了持续的需求。然而，随着精准医疗时代的到来和糖尿病诊疗理念的更新，传统单一剂型的二甲双胍难以满足个体化治疗的需求，尤其集采后，亟待提升二甲双胍的价值。从目前的市场情况看，二甲双胍复方制剂等创新剂型已成为企业的新赛道。米内网和法伯数据显示，口服复方降糖药的市场规模呈现快速增长态势，2022年突破30亿元，同比增长27.3%，2023年涨至37亿元以上。其中，2022年我国总体医疗机构非胰岛素类降糖药物市场中，降糖复方制剂占比为9.7%。这些复方制剂中多以“二甲双胍+”为基础药物：二甲双胍+DPP-4抑制剂（西格列汀二甲双胍）、二甲双胍+SGLT-2抑制剂（二甲双胍恩格列净）、二甲双胍+TZD类（吡格列酮二甲双胍片）和二甲双胍+磺脲类（二甲双胍格列本脲）等。未来，个体化复方组合及长效剂型或成为药企差异化竞争关键。03这些“明星”降糖药适应症不断拓展除二甲双胍外，司美格鲁肽、替尔泊肽等降糖药近年来也展现出超越降糖本身的广阔治疗潜力。多项研究结果显示，司美格鲁肽还能降低心血管疾病高风险患者的主要不良心血管事件发生率达20%；在肥胖的HFpEF伴2型糖尿病的患者中，可达到改善心衰相关症状和体力活动受限，同时达到减重的作用；目前针对非酒精性脂肪性肝炎和阿尔茨海默病的Ⅲ期临床试验正在进行中。 2021年4月，国家药监局批准司美格鲁肽上市，用于治疗2型糖尿病和降低心血管风险；2024年6月，司美格鲁肽“减重版”获批，用于长期体重管理；本月，再次被批准用于降低2型糖尿病合并慢性肾病（CKD）成人患者因心血管疾病而恶化、肾衰竭（终末期肾病）和死亡的风险。礼来公司的替尔泊肽则凭借“双靶点”机制，在SURMOUNT系列研究中展现出优于司美格鲁肽的减重效果。此外，替尔泊肽还能够显著减少呼吸暂停和低通气的次数，改善患者的睡眠质量；可使射血分数保留的心力衰竭伴肥胖患者的心血管死亡或心衰恶化风险降低38%。 2024年5月，替尔泊肽注射液被国家药监局批准用于治疗成人2型糖尿病患者血糖控制，同年7月被获批用于成人长期体重管理。今年7月，再次被批准用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停。从降糖到“全能药”，代谢性疾病药物治疗已进入“多效合一”的新时代。无论是低成本的二甲双胍，还是现在的“超级明星”司美格鲁肽、替尔泊肽，其适应症的拓展都展现了长期的商业价值。新适应症的探索为其市场带来了新的增长点，这也提示药企要在创新研发和市场定位上抢占先机。END内容沟通：郑瑶（13810174402）

2025-07-13

·奇点网

JNCI：二甲双胍又填空白！中国科学家首次发现，炎症性肠病患者服用二甲双胍，与患肠癌风险降低56%相关

*仅供医学专业人士阅读参考已经有不少研究发现，糖尿病患者使用二甲双胍，与患结直肠癌风险较低相关。那如果这些2型糖尿病患者又多一项肠癌风险因素呢？例如，同时患有炎症性肠病。服用二甲双胍与肠癌风险较低之间的相关性，还会存在吗？近日，由我国台北医学大学、中山医学大学和辅仁大学的研究人员组成的研究团队，在著名期刊Journal of the National Cancer Institute上发表了一篇重要研究成果[1]，填补了上述空白。他们基于我国台湾省匹配的1695名使用二甲双胍的炎症性肠病患者与1695名未使用者数据，发现二甲双胍的使用与结直肠癌风险降低56％相关（aHR=0.44），与全因死亡率降低32％相关（aHR=0.68）。而且结直肠癌风险随着累积暴露剂量的增加而下降；累积剂量最高的四分位组风险降低了67％（aHR=0.33）。研究人员基于一个囊括了241590名年龄在20岁及以上的炎症性肠病患者数据库中，进行了倾向评分匹配（PSM），分别筛选了1695名使用二甲双胍的炎症性肠病患者，和相匹配的1695名未使用者二甲双胍的炎症性肠病患者。两组受试者的基线特征均衡良好，平均年龄相近（56.99岁 vs 56.45岁），且约70%的研究对象年龄在51岁以上。在时间依赖性Cox模型分析中，二甲双胍使用与结直肠癌风险降低56%显著相关（aHR=0.44；P=0.0002），还与全因死亡率降低32%显著相关（aHR=0.68；P<0.00001）。这些相关性在所有调整模型中均保持稳定。他们也进行了结直肠癌特异性死亡风险的事后分析。虽然肠癌相关死亡事件的数量有限，但是在所有模型中，二甲双胍的使用仍与较低的肠癌特异性死亡率显著相关。在模型4中，二甲双胍的使用与肠癌特异性死亡风险降低44%相关（aHR=0.56；P=0.0172）。此外，他们还发现累积二甲双胍暴露量与肠癌风险之间存在显著的剂量-反应关系。与最低四分位数（Q1）相比，最高三个四分位数（Q2、Q3和Q4）的完全校正后aHR分别为0.68（Q2）、0.57（Q3）和0.33（Q4），趋势检验具有统计学意义（趋势P值<0.001）。显然，暴露量越高，患肠癌的风险降低越多，最高可降低67%。总的来说，我国研究人员的这项研究成果表明，对于身患炎症性肠病的成人而言，二甲双胍的使用与肠癌风险显著降低有关，而且这种相关性还存在剂量-反应关系。据了解，这也是科学家首次在炎症性肠病患者群体中发现，服用二甲双胍与肠癌风险降低有关。需要指出的是，这一研究结果仍需前瞻性随机研究验证，在临床试验证实上述发现之前，不建议炎症性肠病患者自行服用二甲双胍预防肠癌。参考文献：[1].Huang YJ, Lin JA, Chen WM, Shia BC, Wu SY. Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, Population-Based cohort study. J Natl Cancer Inst. Published online July 2, 2025. doi:10.1093/jnci/djaf165本文作者丨BioTalker

临床结果AHA会议

2025-07-01

·ioncology

ESMO GI 2025明日启幕，中国消化道肿瘤前沿声音响彻巴塞罗那

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA）、2项微型口头报告（MO）、1项教育主题汇报（Education Session）和34篇壁报（Poster）。现将中国之声整理如下，以飨读者。最新突破性摘要（LBA）摘要号：LBA1研究名称：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND TrialFIND试验中期分析：ctDNA甲基化动态监测指导非转移性结直肠癌术后随访讲者：彭俊杰 | 复旦大学附属肿瘤医院会场：Room Madrid时间：7月4日 16:30 - 16:40（当地时间）摘要号：LBA2研究名称：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)TALENTACE研究：比较按需TACE联合阿替利珠单抗+贝伐珠单抗(Atezo+Bev)与单纯按需TACE治疗未经系统治疗的中高肿瘤负荷不可切除肝细胞癌（uHCC）的III期开放标签随机对照研究讲者：韩国宏 | 西安国际医学中心医院会场：Room Barcelona时间：7月3日 14:50 - 15:00（当地时间）微型口头报告（Mini Oral）摘要号：149MO研究名称：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 StudyABSK-011-201研究II期最新结果：依帕戈替尼（ABSK-011）联合阿替利珠单抗用于FGF19过表达型晚期肝细胞癌（HCC）的一线治疗及用于经免疫检查点抑制剂（ICIs）治疗患者的疗效分析讲者：程琪 | 华中科技大学同济医学院附属同济医院会场：Room Barcelona时间：7月2日 17:15 - 17:20（当地时间）摘要号：150MO研究名称：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosisSIERRA研究IIIb期安全性分析：度伐利尤单抗（D）联合替西木单抗（T）一线治疗伴临床预后不良特征的肝细胞癌（HCC）患者讲者：Stephen L. Chan | 香港中文大学会场：Room Barcelona时间：7月2日 17:20 - 17:25（当地时间）教育专题会（Education Session）讲题：New medical treatment in 2025 beyond IO combinations2025年突破免疫联合疗法的新兴医学治疗方向讲者：Stephen L. Chan | 香港中文大学会场：Room Madrid时间：7月3日 12:00 - 12:20（当地时间）壁报（Poster）01结直肠癌摘要号：11P研究名称：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I StudyNALIRIFOX联合靶向治疗一线治疗转移性结直肠癌的I期研究讲者：Haojie Zhou | 复旦大学附属中山医院摘要号：49P研究名称：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer转移性结直肠癌一线诱导治疗后维持策略与治疗间歇的多中心倾向性评分匹配比较研究讲者：Ka Yan Lai | 伊利沙伯医院摘要号：65P研究名称：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal CancerBETTER研究：替雷利珠单抗+贝伐珠单抗+TAS102+SBRT三线治疗MSS/pMMR转移性结直肠癌的开放标签单臂试验讲者：张群 | 南京鼓楼医院摘要号：98P研究名称：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth一种预测早期结直肠癌浸润深度的整合分子标志物的新型风险分层模型讲者：Bing Li | 复旦大学附属中山医院摘要号：130eP研究名称：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer从循证到实践：MSS/MSI-L结直肠癌免疫治疗的多中心真实世界研究与Meta分析讲者：Yue T. Gou | 中南大学湘雅医院摘要号：131eP研究名称：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment贝伐珠单抗+奥沙利铂+伊立替康三联方案治疗氟尿嘧啶经治转移性结直肠癌的疗效与安全性讲者：韩璐 | 中国人民解放军总医院第五医学中心摘要号：139eP研究名称：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)中国结直肠癌MSI/MMR检测与治疗实践全国调研（SUMMER研究）讲者：王正航 | 北京大学肿瘤医院摘要号：146TiP研究名称：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progressMIRACLE3研究：依沃西单抗联合放化疗一线治疗MSS型不可切除肝/肺转移结直肠癌的II期试验（进行中）讲者：李心翔 | 复旦大学附属肿瘤医院摘要号：224P研究名称：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)SPRING-01研究：短程放疗序贯信迪利单抗+CAPOX全直肠新辅助治疗局部进展期直肠癌的前瞻性随机对照试验讲者：田锋 | 山东第一医科大学附属省立医院摘要号：226P研究名称：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results阿得贝利单抗+短程放疗+CAPOX全新辅助治疗pMMR局部进展期直肠癌的中期分析讲者：靖昌庆 | 山东第一医科大学附属省立医院摘要号：229P研究名称：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)高风险局部进展期直肠癌新辅助放化疗±FOLFOXIRI强化治疗的随机研究：临床与生存质量分析（NCT03997435）讲者：Ka Yan Lai | 伊利沙伯医院02肝胆胰肿瘤摘要号：157P研究名称：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analysesCheckMate 9DW研究拓展分析：纳武利尤单抗联合伊匹木单抗 vs 仑伐替尼或索拉非尼一线治疗中国不可切除/晚期肝细胞癌患者讲者：秦叔逵 | 中国药科大学附属南京天印山医院摘要号：183P研究名称：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population中性粒细胞-淋巴细胞比值（NLR）与PLR、LMR、SII、PNI在肝癌冷冻消融术患者中的预后价值比较及最佳适用人群探索讲者：李家平 | 中山大学附属第一医院摘要号：195P研究名称：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinomaCOVID-19、肝硬化与肝细胞癌关联机制的生物信息学与系统生物学研究讲者：Xianxiang Chen | 广西医科大学第一附属医院摘要号：203eP研究名称：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis基于cfDNA生物标志物与人工智能模型的肝癌早期筛查：系统评价与Meta分析讲者：Minh Le | 台北医学大学摘要号：206eP研究名称：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib基线ALBI分级对接受仑伐替尼治疗的肝细胞癌患者预后的影响讲者：商昌珍 | 中山大学孙逸仙纪念医院摘要号：209eP研究名称：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT MechanismRPL41通过转录因子RUNX2介导的上皮间质转化（EMT）机制促进肝细胞癌转移讲者：Zheng A. Hua | 重庆大学附属沙坪坝医院摘要号：302P研究名称：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer索凡替尼联合吉西他滨及白蛋白结合型紫杉醇用于可切除/临界可切除胰腺癌新辅助治疗讲者：高松 | 天津市肿瘤医院摘要号：313P研究名称：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancerABHD17C介导的BCL6B蛋白S-去棕榈酰化通过激活CD24转录抵抗胰腺癌巨噬细胞吞噬讲者：Yalu Zhang | 中国科学技术大学附属第一医院摘要号：317P研究名称：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity肿瘤微环境芯片：异质性下免疫治疗疗效的实时观测窗口讲者：Chiao-Min Lin | 台湾清华大学摘要号：358P研究名称：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study胆道癌根治术后辅助化疗方案的疗效比较：单中心回顾性队列研究讲者：Wen-Ying Lin | 台北荣民总医院03胃食管癌摘要号：394P研究名称：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials卡瑞利珠单抗为基础治疗食管鳞癌的反应性皮肤毛细血管内皮增生（RCCEP）：两项III期试验的合并分析讲者：骆卉妍 | 中山大学肿瘤防治中心摘要号：396P研究名称：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy卡博替尼联合阿替利珠单抗用于含铂化疗失败的复发/转移性食管鳞癌（R/M ESCC）患者：单臂II期研究讲者：Hung-Yang Kuo | 台湾大学医学院附设医院摘要号：399P研究名称：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic ReprogrammingARL5B通过ROCK1-SREBP1介导代谢重编程驱动食管鳞癌进展的机制研究讲者：Xinyue Ma | 山东大学齐鲁医院摘要号：418P研究名称：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study纳武利尤单抗一线治疗晚期胃/胃食管结合部腺癌的真实世界研究结局：多中心回顾性观察研究讲者：邱红 | 华中科技大学同济医学院附属同济医院摘要号：419P研究名称：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)SURPASS研究：中国晚期胃/胃食管结合部癌（GC/GEJC）真实世界治疗模式与生物标志物检测现状调研讲者：Rongrui Liu | 中国人民解放军总医院摘要号：424P研究名称：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study化疗（SOX）联合替雷利珠单抗治疗胃癌肝转移：一项多中心II期研究的首次报告讲者：康牧星 | 浙江大学医学院附属第二医院摘要号：430P研究名称：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical TrialCLDN18.2特异性CAR-T细胞（CT041）治疗胃癌的应答与耐药特征解析：I期临床试验探索性生物标志物分析讲者：彭浩欣 | 北京大学肿瘤医院摘要号：436P研究名称：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions肝切除改善原发性病灶切除的胃癌肝转移患者预后讲者：Yun Feng | 复旦大学附属肿瘤医院04其他摘要号：219eP研究名称：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study转移性胃肠间质瘤行肿瘤细胞减灭术的预后因素分析：一项回顾性队列研究讲者：Haidong Zhang | 四川大学华西医院摘要号：495P研究名称：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction初始剂量减量策略改善老年胃肠道肿瘤患者化疗耐受性的优化研究讲者：Wendy W. Chan | 香港玛丽医院摘要号：499P研究名称：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapyTACR1基因型与含奥氮平止吐方案防治化疗相关性呕吐的疗效关联研究讲者：Winnie Yeo | 香港中文大学摘要号：505eP研究名称：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers安罗替尼治疗贝伐珠单抗经治胃肠道肿瘤的真实世界疗效讲者：陈锦章 | 南方医科大学南方医院摘要号：506eP研究名称：Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study基于CARG评估指导抗肿瘤治疗剂量调整对中国老年癌症患者不良事件的影响：前瞻性研究讲者：葛郁平 | 北京协和医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期免疫疗法临床结果

100 项与台北医学大学相关的药物交易

登录后查看更多信息

100 项与台北医学大学相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年08月29日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Anti-CEACAM HCAb-ADC(Taipei Medical University) ( CEACAM6 )	结直肠癌更多	临床前
NSC361563 ( DYRK1A )	阿尔茨海默症更多	临床前
AptBCis2 ( DNA )	恶病质更多	临床前
3-Monothiopomamalomide	神经炎性疾病更多	临床前
BA-5 ( LPS x TGF-β1 )	肝细胞癌更多	临床前